{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"Adlai Nortye Ltd."},"Symbol":{"label":"Symbol","value":"ANL"},"Address":{"label":"Address","value":"UGLAND HOUSE,PO BOX 309, GRAND CAYMAN, Cayman Islands"},"Phone":{"label":"Phone","value":"848 230 7430"},"Industry":{"label":"Industry","value":"Biotechnology: Pharmaceutical Preparations"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"Caribbean"},"CompanyDescription":{"label":"Company Description","value":"Adlai Nortye Ltd is a global clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The Company's pipeline includes three clinical-stage drug candidates, buparlisib (AN2025), palupiprant (AN0025), and AN4005, as well as three preclinical candidates. AN2025 is a pan-phosphoinositide 3-kinase (PI3K) inhibitor that is designed to act against solid tumors. AN2025 is undergoing Phase III, open-label clinical trial for the treatment of recurrent or metastatic head and neck squamous cell carcinomas (HNSCC) after anti-programmed death-1 (PD-1) or its ligand (PD-L1) treatment. AN0025 is a small molecule prostaglandin E receptor 4 (EP4) antagonist. AN4005 is an internally discovered oral small molecule PD-L1 inhibitor in development to induce and stabilize PD-L1 dimerization and thereby disrupt the interaction between PD-1 and PD-L1. Its preclinical candidates include: AN8025, AN1025, and AN9025."},"CompanyUrl":{"label":"Company Url","value":"https://www.adlainortye.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"Kai Yang Tang","title":"Global Head-Clinical Operations & Senior VP"},{"name":"Ngai Chiu Tse","title":"Head-Research & Development"},{"name":"Yang Lu","title":"Chairman & Chief Executive Officer"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}